Upstream Bio Reports Q2 2026: $261M Cash, Phase 3 Starts in Q1 2027
UPB sits 24% above its 52-week low of $5.85.
Summary
Upstream Bio reported Q2 2026 financials with $261.3 million in cash and provided clinical updates: Phase 3 trials in severe asthma and CRSwNP to start in Q1 2027, with Phase 2 LTE and COPD data expected in H2 2027.
Key Events · Earnings and Guidance · UPB
-
Cash Runway Through 2027
Cash, equivalents, and short-term investments totaled $261.3 million as of June 30, 2026, sufficient to fund operations through 2027 per management.
-
Phase 3 Initiation in Q1 2027
Company plans to begin dosing in Phase 3 trials for severe asthma and CRSwNP in the first quarter of 2027, prioritizing quarterly at-home administration.
-
Phase 2 Data Readouts in H2 2027
Phase 2 LTE (severe asthma) and Phase 2 COPD trial data are expected in the second half of 2027, providing near-term catalysts.
-
Modest ATM Usage
During Q2 2026, 239,797 shares were sold under the ATM program for net proceeds of $2.1 million, representing disciplined capital access.
Analysis · UPB · Life Sciences
Upstream Bio's Q2 2026 filing confirms a solid cash position of $261.3 million, extending runway through 2027, and sets a clear timeline for Phase 3 initiations in severe asthma and CRSwNP in Q1 2027. The net loss of $39.7 million is in line with expectations for a clinical-stage biotech, and the modest ATM usage ($2.1M) suggests disciplined capital management. The clinical updates — Phase 2 LTE and COPD data in H2 2027 — provide near-term catalysts, while the Phase 3 start keeps the pivotal program on track. This filing reinforces the company's ability to fund its lead asset through key value inflection points without immediate dilution risk.
At the time of this filing, UPB was trading at $7.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $404.9M. The 52-week trading range was $5.85 to $33.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.